In vivo and in situ programming of tumor immunity by combining oncolytics and PD-1 immune checkpoint blockade

Area of Science:

• Immunology
• Oncology
• Virology

Background:

• The programmed cell death protein 1 (PD1) pathway is a validated target for cancer immunotherapy.
• Current PD1 blockade strategies exhibit limited patient response rates and significant immune-related adverse events.
• There is a need for novel therapeutic approaches to improve PD1-based cancer treatment.

Purpose of the Study:

• To evaluate the efficacy and safety of a novel intra-tumoral oncolytic virus expressing a truncated PD1 protein.
• To assess the potential of local viral delivery to overcome limitations of systemic PD1 blockade.

Main Methods:

• Development of a modified oncolytic myxoma virus engineered to express a truncated PD1 protein.
• Administration of the modified virus directly into tumors in a preclinical melanoma model.
• Assessment of anti-tumor efficacy and systemic toxicity.

Main Results:

• Intra-tumoral administration of the modified oncolytic virus demonstrated enhanced anti-tumor efficacy.
• The local delivery approach resulted in reduced systemic toxicity compared to conventional PD1 blockade.
• The engineered virus effectively targeted tumor cells and modulated the tumor microenvironment.

Conclusions:

• Local, intra-tumoral delivery of an oncolytic virus expressing truncated PD1 is a promising strategy for cancer therapy.
• This approach offers a potential method to improve efficacy and mitigate the toxicity associated with PD1 pathway blockade.
• Further research into oncolytic virotherapy holds potential for advancing cancer treatment paradigms.